Source: Northern Financial Review

Rosemont acquired Sarras Health for undisclosed amount

Read full article »

Rosemont's Competitors | Rosemont's News | Rosemont's Financials

Followers on Owler

3

Est. Annual Revenue

$25-100M

Est. Employees

100-250

CEO

Howard Taylor

CEO Approval Rating

- -/100

Rosemont develops, manufactures and supplies liquid medicines for the treatment of dysphasia.